Mereo BioPharma Group plc (MREO)

Etorro trading 970x250
Mereo BioPharma Group plc (MREO) Logo

About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom. Address: 1 Cavendish Place, London, United Kingdom, W1G 0QF

Mereo BioPharma Group plc News and around…

Latest news about Mereo BioPharma Group plc (MREO) common stock and company :

Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment
13 Oct, 2021 Yahoo! Finance

Living With Osteogenesis IMPerfecta: UnderstAnding Experiences Based On Community InsighT and Evidence Survey, the IMPACT SurveyMore than 2200 individual responses collected over a 3-month period from some 65 countries in 8 languagesSet to be the largest global gathering of data to date about the impact that Osteogenesis Imperfecta (OI) has on people with OI, families and caregivers LONDON and REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mere

Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
01 Oct, 2021 Yahoo! Finance

Previously reported data demonstrated dose-dependent, statistically significant bone-building effect at multiple anatomical sites in adult patients with OI that was consistent across subtypes of OI Dose-dependent improvements in serum biomarkers of bone turnover with UX143 therapy confirm sclerostin inhibition mechanism of action LONDON and NOVATO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and c

12 Health Care Stocks Moving In Thursday's After-Market Session
30 Sep, 2021 FinancialContent

Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 4.99% to $10.73 during Thursday's after-market session. The company's market ...

Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors
20 Sep, 2021 FinancialContent
Mereo BioPharma to Participate in Three Upcoming Investor Conferences
09 Sep, 2021 FinancialContent
Mereo BioPharma to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference
02 Aug, 2021 FinancialContent
Hedge Funds Are Crazy About Mereo BioPharma Group plc (MREO)
19 Jul, 2021 Yahoo! Finance

The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

Interesting MREO Put Options For September 17th
16 Jul, 2021 FinancialContent

Investors in Mereo BioPharma Group PLC (MREO) saw new options begin trading this week, for the September 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MREO options chain for the new September 17th contracts and identified the following put contract of particular interest.

9 Top Reddit Penny Stocks For Your Summer 2021 Watchlist
02 Jul, 2021 FinancialContent
10 Top Penny Stocks On Robinhood To Watch Right Now Before July 2021
19 Jun, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's Pre-Market Session
14 Jun, 2021 FinancialContent

Gainers Enochian BioSciences (NASDAQ:ENOB) stock increased by 147.84% to $10.93 during Monday's pre-market session. ...

Mereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome
02 Jun, 2021 FinancialContent

Mereo BioPharma Group plc(NASDAQ: MREO)has announced data from an interim analysisof an investigator-initiated ...

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)
02 Jun, 2021 FinancialContent
Mereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
27 May, 2021 FinancialContent
First Week of July 16th Options Trading For Mereo BioPharma Group (MREO)
21 May, 2021 FinancialContent

Investors in Mereo BioPharma Group PLC (MREO) saw new options become available this week, for the July 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MREO options chain for the new July 16th contracts and identified one put and one call contract of particular interest.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 May, 2021 FinancialContent

Gainers Second Sight Medical (NASDAQ:EYES) shares increased by 25.39% to $6.27 during Wednesday's pre-market ...

Investors Snag MREO Even Lower Than Its Secondary Stock Offering
11 May, 2021 FinancialContent

Looking back to 90 days ago, Mereo BioPharma Group PLC (MREO) priced a 34,500,000 share secondary stock offering at $2.90 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2021
05 May, 2021 FinancialContent

Upgrades Atlantic Equities upgraded the previous rating for Under Armour Inc (NYSE:UAA) from Underweight to Neutral. ...

Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021
04 May, 2021 FinancialContent
Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab
30 Apr, 2021 FinancialContent

Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center andMereo BioPharma ...

Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer
30 Apr, 2021 FinancialContent

Study to be Conducted at The University of Texas MD Anderson Cancer Center

June 18th Options Now Available For Mereo BioPharma Group (MREO)
16 Apr, 2021 FinancialContent

Investors in Mereo BioPharma Group PLC (MREO) saw new options begin trading today, for the June 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MREO options chain for the new June 18th contracts and identified one put and one call contract of particular interest.

55 Biggest Movers From Yesterday
13 Apr, 2021 FinancialContent

Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company ...

42 Stocks Moving In Monday's Mid-Day Session
12 Apr, 2021 FinancialContent

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the company's 13D filing showed that ...

4 Top Biotech Penny Stocks to Watch in April 2021
09 Apr, 2021 FinancialContent
Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
08 Apr, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's Intraday Session
05 Apr, 2021 FinancialContent

Gainers Chembio Diagnostics (NASDAQ:CEMI) stock moved upwards by 58.52% to $5.58 during Monday's regular session. As ...

Hot Penny To Buy According To Analysts With Price Targets Up To 195%
05 Apr, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2021
05 Apr, 2021 FinancialContent

Upgrades For Valero Energy Corp (NYSE:VLO), Tudor Pickering upgraded the previous rating of Hold to Buy. Valero Energy ...

Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
31 Mar, 2021 FinancialContent

Mereo BioPharma Group plc (MREO) is a NASDAQ Common Stock listed in , ,

970x250